All In Biotech

Drug Trial Radar · NCT01697722

Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy

A Retrospective Evaluation of Effectiveness and Cost-effectiveness of Extrafine HFA-BDP Compared With Combination ICS/LABA Therapy in the Management of Asthma in a Representative Population of UK Primary Care Patients

Last checked: Nov 19, 2026Latest source record: Oct 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

815,377

Actual

Start

Jan 1991

Primary completion

Jun 2007

Study completion Feb 2010

Sponsor

Lead sponsor
Research in Real-Life LtdResearch network
Sponsor type
Research network
Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
First posted
Oct 2, 2012

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 5 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the effectiveness, cost-effectiveness and direct healthcare costs of asthma management in patients with evidence of persistent asthma following an increase in asthma therapy in the form of either an increased dose of inhaled glucocorticosteroids (ICS) using extrafine hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) via pressurised metered-dose inhaler (pMDI) or breath-actuated inhaler (BAI), or a change to combination ICS plus long-acting bronchodilator (LABA) therapy using fixed combinations (fluticasone propionate / salmeterol \[FP/SAL\] or budesonide / formoterol \[BUD/FOR\]) or separate pMDIs and BAIs.

Conditions

  • Asthma

Interventions

  • Extra-fine hydrofluoroalkane-beclometasone dipropionateDrug

    Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI

  • ICS / LABA via separate pMDI and / or BAI inhalersDrug

    A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proxy asthma controlTime frame: One-year outcome period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Practice Research Database

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.